University of California San Francisco

Publications

Publications

  1. ASO Visual Abstract: A Multi-institutional Analysis of Contralateral Axillary Metastases-Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
    2025 | PubMed
  2. Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.
    2025 | UCSF Research Profile
  3. Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
    2025 | UCSF Research Profile
  4. I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
    2025 | UCSF Research Profile
  5. Patient experiences of diagnosis and treatment of invasive lobular carcinoma: A qualitative study from a prospective registry.
    2025 | UCSF Research Profile
  6. Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.
    2025 | UCSF Research Profile
  7. Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
    2025 | UCSF Research Profile
  8. Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
    2025 | UCSF Research Profile
  9. ASO Visual Abstract: Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-Analysis Evaluating the Impact of Oncoplastic Surgery.
    2025 | PubMed
  10. A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
    2025 | PubMed
  11. Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery.
    2025 | PubMed
  12. Abstract 2367: Changes in breast hormone signaling and inflammation underlie radiologic features of cancer risk.
    2025 | UCSF Research Profile
  13. 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ.
    2025 | UCSF Research Profile
  14. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
    2025 | PubMed
  15. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
    2025 | PubMed
  16. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
    2024 | PubMed
  17. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    2024 | PubMed
  18. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    2024 | PubMed
  19. Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
    2024 | PubMed
  20. Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast.
    2024 | PubMed
  21. Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
    2024 | UCSF Research Profile
  22. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.
    2024 | PubMed
  23. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    2024 | PubMed
  24. ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial.
    2024 | PubMed
  25. ASO Author Reflections: Detecting Local Recurrence After Primary Treatment for Invasive Lobular Carcinoma of the Breast.
    2024 | PubMed
  26. International survey on invasive lobular breast cancer identifies priority research questions.
    2024 | PubMed
  27. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    2024 | PubMed
  28. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    2024 | PubMed
  29. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
    2024 | PubMed
  30. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
    2024 | UCSF Research Profile
  31. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
    2024 | UCSF Research Profile
  32. The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes.
    2024 | UCSF Research Profile
  33. Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
    2024 | UCSF Research Profile
  34. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
    2024 | UCSF Research Profile
  35. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
    2024 | PubMed
  36. ASO Author Reflections: The Oncologic Safety of Immediate Oncoplastic Approaches in Invasive Lobular Carcinoma.
    2024 | PubMed
  37. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    2024 | PubMed
  38. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
    2024 | UCSF Research Profile
  39. Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
    2024 | UCSF Research Profile
  40. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    2024 | PubMed
  41. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
    2024 | UCSF Research Profile
  42. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.
    2024 | PubMed
  43. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
    2024 | PubMed
  44. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2024 | PubMed
  45. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    2023 | PubMed
  46. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  47. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
    2023 | PubMed
  48. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns".
    2023 | PubMed
  49. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    2023 | PubMed
  50. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
    2023 | UCSF Research Profile
  51. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
    2023 | PubMed
  52. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2023 | PubMed
  53. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma.
    2023 | PubMed
  54. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  55. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    2023 | PubMed
  56. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    2023 | PubMed
  57. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    2023 | PubMed
  58. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    2023 | PubMed
  59. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast.
    2023 | PubMed
  60. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer.
    2023 | PubMed
  61. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    2023 | PubMed
  62. Metabolic Positron Emission Tomography in Breast Cancer.
    2023 | PubMed
  63. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    2023 | PubMed
  64. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    2023 | PubMed
  65. Time to Surgery in Breast Cancer-Is Faster Always Better?
    2023 | PubMed
  66. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
    2023 | UCSF Research Profile
  67. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
    2023 | UCSF Research Profile
  68. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | PubMed
  69. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | UCSF Research Profile
  70. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | UCSF Research Profile
  71. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
    2023 | UCSF Research Profile
  72. Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas.
    2023 | UCSF Research Profile
  73. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
    2023 | UCSF Research Profile
  74. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    2023 | PubMed
  75. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    2023 | PubMed
  76. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    2022 | PubMed
  77. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
    2022 | PubMed
  78. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
    2022 | PubMed
  79. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    2022 | PubMed
  80. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    2022 | UCSF Research Profile
  81. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
    2022 | PubMed
  82. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    2022 | UCSF Research Profile
  83. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
    2022 | PubMed
  84. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
    2022 | PubMed
  85. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    2022 | UCSF Research Profile
  86. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    2022 | UCSF Research Profile
  87. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    2022 | PubMed
  88. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    2022 | PubMed
  89. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    2022 | UCSF Research Profile
  90. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
    2022 | UCSF Research Profile
  91. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
    2022 | UCSF Research Profile
  92. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
    2022 | UCSF Research Profile
  93. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
    2022 | UCSF Research Profile
  94. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    2021 | PubMed
  95. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
    2021 | UCSF Research Profile
  96. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    2021 | PubMed
  97. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    2021 | PubMed
  98. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    2021 | PubMed
  99. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    2021 | PubMed
  100. Correction to: Applications of 3D printing in breast cancer management.
    2021 | PubMed
  101. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    2021 | PubMed
  102. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
    2021 | UCSF Research Profile
  103. Early onset, multiple, bilateral fibroadenomas of the breast: a case report.
    2021 | PubMed
  104. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
    2021 | UCSF Research Profile
  105. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial.
    2021 | PubMed
  106. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    2021 | PubMed
  107. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response.
    2021 | PubMed
  108. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    2021 | PubMed
  109. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    2021 | PubMed
  110. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
    2021 | UCSF Research Profile
  111. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
    2021 | UCSF Research Profile
  112. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
    2021 | UCSF Research Profile
  113. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
    2021 | UCSF Research Profile
  114. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    2021 | PubMed
  115. Applications of 3D printing in breast cancer management.
    2021 | PubMed
  116. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    2021 | PubMed
  117. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    2021 | PubMed
  118. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    2020 | PubMed
  119. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    2020 | PubMed
  120. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
    2020 | UCSF Research Profile
  121. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    2020 | PubMed
  122. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    2020 | PubMed
  123. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    2020 | PubMed
  124. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
    2020 | UCSF Research Profile
  125. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
    2020 | UCSF Research Profile
  126. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    2020 | PubMed
  127. Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry.
    2020 | UCSF Research Profile
  128. Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.
    2020 | UCSF Research Profile
  129. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
    2020 | UCSF Research Profile
  130. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
    2020 | UCSF Research Profile
  131. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
    2020 | UCSF Research Profile
  132. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
    2020 | UCSF Research Profile
  133. Pragmatic Trials and Approaches to Transforming Care.
    2020 | UCSF Research Profile
  134. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    2019 | PubMed
  135. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    2019 | PubMed
  136. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast.
    2019 | PubMed
  137. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    2019 | PubMed
  138. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | PubMed
  139. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
    2019 | PubMed
  140. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
    2019 | UCSF Research Profile
  141. Changes in mammographic density following bariatric surgery.
    2019 | PubMed
  142. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
    2019 | UCSF Research Profile
  143. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
    2019 | UCSF Research Profile
  144. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | UCSF Research Profile
  145. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
    2019 | UCSF Research Profile
  146. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2019 | PubMed
  147. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    2018 | PubMed
  148. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  149. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2018 | PubMed
  150. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  151. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
    2018 | UCSF Research Profile
  152. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
    2018 | UCSF Research Profile
  153. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
    2018 | UCSF Research Profile
  154. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
    2018 | UCSF Research Profile
  155. Breast tumor location in BRCA mutation carriers and implications for prevention.
    2017 | UCSF Research Profile
  156. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    2016 | PubMed
  157. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    2016 | PubMed
  158. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    2015 | PubMed
  159. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    2015 | PubMed
  160. Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ.
    2015 | UCSF Research Profile
  161. Abstract 165: Suppressed immunity and macrophages characterize high risk high grade DCIS.
    2014 | UCSF Research Profile
  162. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    2013 | PubMed
  163. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    2013 | PubMed
  164. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    2012 | PubMed
  165. Biology of breast cancer in Nigerian women: a pilot study.
    2012 | PubMed
  166. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    2012 | PubMed
  167. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
    2011 | UCSF Research Profile
  168. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
    2011 | UCSF Research Profile
  169. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
    2011 | UCSF Research Profile
  170. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    2011 | PubMed
  171. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
    2011 | UCSF Research Profile
  172. Benign Thoracic Disease in the Elderly.
    2011 | UCSF Research Profile
  173. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    2011 | PubMed
  174. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
    2010 | UCSF Research Profile
  175. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
    2010 | UCSF Research Profile
  176. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence.
    2009 | PubMed
  177. Bacteriologic features of surgical site infections following breast surgery.
    2009 | PubMed
  178. Benign thoracic disease in the elderly.
    2009 | PubMed
  179. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections.
    2009 | PubMed
  180. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum.
    2005 | PubMed
  181. Quality-of-life issues in psoriasis.
    2004 | PubMed